These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 180871)

  • 1. The effects of calcium and phosphorus in hemodialysis.
    Goldsmith RS
    Annu Rev Med; 1976; 27():181-90. PubMed ID: 180871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Management of renal osteopathy in patients with chronic dialysis].
    Kiss D; Brunner FP
    Schweiz Med Wochenschr; 1996 Oct; 126(42):1792-8. PubMed ID: 8966512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mineral metabolism and renal bone disease: effects of CAPD versus hemodialysis.
    Coburn JW
    Kidney Int Suppl; 1993 Feb; 40():S92-100. PubMed ID: 8445845
    [No Abstract]   [Full Text] [Related]  

  • 5. Disordered divalent ion metabolism in kidney disease: comments on pathogenesis and treatment.
    Kleeman CR; Better OS
    Kidney Int; 1973 Aug; 4(2):73-9. PubMed ID: 4364428
    [No Abstract]   [Full Text] [Related]  

  • 6. Calcium and phosphorus in diet therapy of uremia.
    Schoolwerth AC; Engle JE
    J Am Diet Assoc; 1975 May; 66(5):460-4. PubMed ID: 1123506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of high dialysate calcium concentration on bone remodelling, serum biochemistry, and parathyroid hormone in patients with renal osteodystrophy.
    Drüeke T; Bordier PJ; Man NK; Jungers P; Marie P
    Kidney Int; 1977 Apr; 11(4):267-74. PubMed ID: 857076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Renal osteodystrophy. I. Recent pathophysiological acquisitions (author's transl)].
    Sebert JL; Fournier A; Gueris J; Marie P; Coevoet B; de Fremont JF; Lambrey G; Kuntz D
    Nouv Presse Med; 1977 Nov; 6(37):3419-24. PubMed ID: 341075
    [No Abstract]   [Full Text] [Related]  

  • 9. Renal osteodystrophy and aluminum bone disease in CAPD patients.
    Gokal R
    Clin Nephrol; 1988; 30 Suppl 1():S64-7. PubMed ID: 3052962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mineral and bone disorders in patients on dialysis: physiology and clinical consequences.
    McCarley PB; Arjomand M
    Nephrol Nurs J; 2008; 35(1):59-64. PubMed ID: 18372764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of calcium and phosphorus on patients maintained on dialysis.
    Goldsmith RS; Arnaud CD; Johnson WJ
    Kidney Int Suppl; 1975 Jan; (2):118-22. PubMed ID: 1099298
    [No Abstract]   [Full Text] [Related]  

  • 12. Renal osteodystrophy--pathogenesis and treatment.
    Cushner HM; Adams ND
    Am J Med Sci; 1985 Dec; 290(6):234-45. PubMed ID: 3909812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
    Torres PU
    J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Renal osteodystrophy-II-Recent therapeutic acquisitions (author's transl)].
    Sebert JL; Fournier AE; Gueris J; Marie P; Coevoet B; de Fremont JF; Lambrey G; Kuntz D
    Nouv Presse Med; 1977 Nov; 6(38):3533-7. PubMed ID: 341079
    [No Abstract]   [Full Text] [Related]  

  • 15. Differential effects of paricalcitol and calcitriol on intestinal calcium absorption in hemodialysis patients.
    Lund RJ; Andress DL; Amdahl M; Williams LA; Heaney RP
    Am J Nephrol; 2010; 31(2):165-70. PubMed ID: 20016142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of bone remodeling: impact of novel therapies.
    Hercz G
    Semin Dial; 2001; 14(1):55-60. PubMed ID: 11208041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How do calcimimetics fit into the management of parathyroid hormone, calcium, and phosphate disturbances in dialysis patients?
    Shahapuni I; Mansour J; Harbouche L; Maouad B; Benyahia M; Rahmouni K; Oprisiu R; Bonne JF; Monge M; El Esper N; Presne C; Moriniere P; Choukroun G; Fournier A
    Semin Dial; 2005; 18(3):226-38. PubMed ID: 15934970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abnormal mineral metabolism and mortality in hemodialysis patients with secondary hyperparathyroidism: evidence from marginal structural models used to adjust for time-dependent confounding.
    Fukagawa M; Kido R; Komaba H; Onishi Y; Yamaguchi T; Hasegawa T; Kurita N; Fukuma S; Akizawa T; Fukuhara S
    Am J Kidney Dis; 2014 Jun; 63(6):979-87. PubMed ID: 24119541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intestinal calcium absorption, serum phosphate, and parathyroid hormone in patients with chronic renal failure and osteodystrophy before and during hemodialysis.
    Juttmann JR; Hagenouw-Taal JC; Lameyer LD; Ruis AM; Birkenhäger JC
    Calcif Tissue Res; 1978 Dec; 26(2):119-26. PubMed ID: 737558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.